vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and CPI Card Group Inc. (PMTS). Click either name above to swap in a different company.
CPI Card Group Inc. is the larger business by last-quarter revenue ($153.1M vs $86.8M, roughly 1.8× IOVANCE BIOTHERAPEUTICS, INC.). On growth, CPI Card Group Inc. posted the faster year-over-year revenue change (22.3% vs 17.7%). CPI Card Group Inc. produced more free cash flow last quarter ($35.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 16.9%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CPI Card Group Inc. is a leading provider of payment card production and associated solutions, including contactless and contact credit/debit cards, prepaid cards, and card personalization services. It primarily serves financial institutions, fintech firms, and retail brands across its core North American market.
IOVA vs PMTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $153.1M |
| Net Profit | — | $7.3M |
| Gross Margin | 67.4% | 31.5% |
| Operating Margin | -84.7% | 12.0% |
| Net Margin | — | 4.8% |
| Revenue YoY | 17.7% | 22.3% |
| Net Profit YoY | — | 8.5% |
| EPS (diluted) | — | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $153.1M | ||
| Q3 25 | $67.5M | $138.0M | ||
| Q2 25 | $60.0M | $129.8M | ||
| Q1 25 | $49.3M | $122.8M | ||
| Q4 24 | $73.7M | $125.1M | ||
| Q3 24 | $58.6M | $124.8M | ||
| Q2 24 | $31.1M | $118.8M | ||
| Q1 24 | $715.0K | $111.9M |
| Q4 25 | — | $7.3M | ||
| Q3 25 | $-91.3M | $2.3M | ||
| Q2 25 | $-111.7M | $518.0K | ||
| Q1 25 | $-116.2M | $4.8M | ||
| Q4 24 | — | $6.8M | ||
| Q3 24 | $-83.5M | $1.3M | ||
| Q2 24 | $-97.1M | $6.0M | ||
| Q1 24 | $-113.0M | $5.5M |
| Q4 25 | 67.4% | 31.5% | ||
| Q3 25 | 43.0% | 29.7% | ||
| Q2 25 | 5.5% | 30.9% | ||
| Q1 25 | -0.8% | 33.2% | ||
| Q4 24 | 68.7% | 34.1% | ||
| Q3 24 | 46.2% | 35.8% | ||
| Q2 24 | -0.8% | 35.7% | ||
| Q1 24 | — | 37.1% |
| Q4 25 | -84.7% | 12.0% | ||
| Q3 25 | -140.7% | 9.4% | ||
| Q2 25 | -189.8% | 7.3% | ||
| Q1 25 | -245.8% | 11.5% | ||
| Q4 24 | -117.5% | 12.7% | ||
| Q3 24 | -152.1% | 14.3% | ||
| Q2 24 | -327.6% | 12.5% | ||
| Q1 24 | -16464.6% | 12.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | -135.3% | 1.7% | ||
| Q2 25 | -186.2% | 0.4% | ||
| Q1 25 | -235.5% | 3.9% | ||
| Q4 24 | — | 5.4% | ||
| Q3 24 | -142.7% | 1.0% | ||
| Q2 24 | -312.2% | 5.1% | ||
| Q1 24 | -15800.8% | 4.9% |
| Q4 25 | — | $0.62 | ||
| Q3 25 | — | $0.19 | ||
| Q2 25 | $-0.33 | $0.04 | ||
| Q1 25 | $-0.36 | $0.40 | ||
| Q4 24 | $-0.24 | $0.56 | ||
| Q3 24 | $-0.28 | $0.11 | ||
| Q2 24 | $-0.34 | $0.51 | ||
| Q1 24 | $-0.42 | $0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $21.7M |
| Total DebtLower is stronger | — | $286.7M |
| Stockholders' EquityBook value | $698.6M | $-17.3M |
| Total Assets | $913.2M | $403.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $21.7M | ||
| Q3 25 | $300.8M | $16.0M | ||
| Q2 25 | $301.2M | $17.1M | ||
| Q1 25 | $359.7M | $31.5M | ||
| Q4 24 | $323.8M | $33.5M | ||
| Q3 24 | $397.5M | $14.7M | ||
| Q2 24 | $412.5M | $7.5M | ||
| Q1 24 | $356.2M | $17.1M |
| Q4 25 | — | $286.7M | ||
| Q3 25 | — | $308.4M | ||
| Q2 25 | — | $310.9M | ||
| Q1 25 | — | $280.7M | ||
| Q4 24 | — | $280.4M | ||
| Q3 24 | — | $280.2M | ||
| Q2 24 | — | $269.7M | ||
| Q1 24 | — | $265.3M |
| Q4 25 | $698.6M | $-17.3M | ||
| Q3 25 | $702.3M | $-25.7M | ||
| Q2 25 | $698.5M | $-29.0M | ||
| Q1 25 | $767.9M | $-29.7M | ||
| Q4 24 | $710.4M | $-35.6M | ||
| Q3 24 | $773.5M | $-42.8M | ||
| Q2 24 | $768.5M | $-44.6M | ||
| Q1 24 | $680.0M | $-48.5M |
| Q4 25 | $913.2M | $403.2M | ||
| Q3 25 | $904.9M | $407.1M | ||
| Q2 25 | $907.4M | $399.8M | ||
| Q1 25 | $966.7M | $351.9M | ||
| Q4 24 | $910.4M | $349.7M | ||
| Q3 24 | $991.1M | $342.3M | ||
| Q2 24 | $964.3M | $321.4M | ||
| Q1 24 | $869.8M | $319.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $39.6M |
| Free Cash FlowOCF − Capex | $-61.9M | $35.2M |
| FCF MarginFCF / Revenue | -71.3% | 23.0% |
| Capex IntensityCapex / Revenue | 10.7% | 2.9% |
| Cash ConversionOCF / Net Profit | — | 5.39× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $41.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $39.6M | ||
| Q3 25 | $-78.7M | $10.0M | ||
| Q2 25 | $-67.4M | $4.3M | ||
| Q1 25 | $-103.7M | $5.6M | ||
| Q4 24 | $-73.3M | $26.7M | ||
| Q3 24 | $-59.0M | $12.5M | ||
| Q2 24 | $-98.4M | $-4.8M | ||
| Q1 24 | $-122.3M | $8.9M |
| Q4 25 | $-61.9M | $35.2M | ||
| Q3 25 | $-89.5M | $5.3M | ||
| Q2 25 | $-74.9M | $533.0K | ||
| Q1 25 | $-109.9M | $292.0K | ||
| Q4 24 | $-77.5M | $21.6M | ||
| Q3 24 | $-61.3M | $11.1M | ||
| Q2 24 | $-98.9M | $-6.0M | ||
| Q1 24 | $-126.5M | $7.4M |
| Q4 25 | -71.3% | 23.0% | ||
| Q3 25 | -132.7% | 3.8% | ||
| Q2 25 | -124.9% | 0.4% | ||
| Q1 25 | -222.8% | 0.2% | ||
| Q4 24 | -105.1% | 17.3% | ||
| Q3 24 | -104.6% | 8.9% | ||
| Q2 24 | -317.9% | -5.0% | ||
| Q1 24 | -17685.3% | 6.6% |
| Q4 25 | 10.7% | 2.9% | ||
| Q3 25 | 16.1% | 3.4% | ||
| Q2 25 | 12.4% | 2.9% | ||
| Q1 25 | 12.6% | 4.3% | ||
| Q4 24 | 5.7% | 4.0% | ||
| Q3 24 | 3.9% | 1.2% | ||
| Q2 24 | 1.4% | 1.0% | ||
| Q1 24 | 583.4% | 1.3% |
| Q4 25 | — | 5.39× | ||
| Q3 25 | — | 4.32× | ||
| Q2 25 | — | 8.39× | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | 3.94× | ||
| Q3 24 | — | 9.70× | ||
| Q2 24 | — | -0.79× | ||
| Q1 24 | — | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
PMTS
| US Debit And Credit | $128.9M | 84% |
| US Prepaid Debit | $24.4M | 16% |
